Estimating risk for developing epilepsy A population-based study in Rochester, Minnesota

G.H. Sergievsky Center, 630 West 168th Street, P&S Unit 16, New York, NY 10032, USA.
Neurology (Impact Factor: 8.29). 01/2011; 76(1):23-7. DOI: 10.1212/WNL.0b013e318204a36a
Source: PubMed


Previous studies that have assessed the risk of developing epilepsy have failed to account for the competing risk of death, significant in the elderly where epilepsy incidence is highest. We report the lifetime risk for epilepsy, accounting for the competing risk of mortality.
Lifetime risk and cumulative incidence of epilepsy were examined among Rochester, MN, residents between 1960 and 1979. Age-, gender-, and calendar year-specific deaths were obtained for Rochester, MN. Lifetime risk was calculated as the conditional probability of developing epilepsy by a specific age for a person reaching that age who had not yet developed epilepsy. Lifetime risk and cumulative incidence were compared for age and time period.
We identified 412 individuals with incident epilepsy diagnosed between January 1, 1960, and December 31, 1979. Lifetime risk was 1.6% to age 50 and 3.0% to age 80; cumulative incidence was 1.7% to age 50 and 3.4% to age 80. Similar differences were seen across epilepsy etiologies. Lifetime risk through 87 years of age increased over time from 3.5% in 1960-1969 to 4.2% in 1970-1979.
One in 26 people will develop epilepsy during their lifetime. Lifetime risk provides an estimate of an individual's risk for epilepsy over his or her remaining lifetime, translates into the number of people who are expected to develop epilepsy, and assists health care planners as they estimate service needs for epilepsy.

Download full-text


Available from: Giancarlo Logroscino, Dec 17, 2013
  • Source
    • "Epilepsy is a condition of the brain characterized by recurrent seizures that affect 1–2% (Hesdorffer et al., 2011) of the population worldwide. Mesial temporal lobe epilepsy (MTLE) is the most frequent form of focal epilepsy in adults and at least 70% of patients presenting with MTLE are resistant to currently available medication (Schmidt and Löscher, 2005; Engel, 2001). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Epilepsy is a condition of the brain that occurs in many different forms. For obvious reasons, understanding the complex mechanisms underlying the process of epileptogenesis cannot be fully acquired in clinical studies or analyses of surgically resected human epileptic specimens. Accordingly, a variety of animal models have been developed that recapitulate different aspects of the various forms of epilepsies. In our review we mainly focus on those chemically induced models that recapitulate characteristics typically seen in human temporal lobe epilepsies. By comparing models based on topical application of different agents, advantages and disadvantages are discussed with respect to parameters including reliability and mortality, as well as the similarity with the human condition of functional and morphological alterations occurring in different brain regions in the course of epileptogenesis and in the chronic state. Copyright © 2015. Published by Elsevier B.V.
    Full-text · Article · May 2015 · Journal of Neuroscience Methods
  • Source
    • "of autism, Parkinson's, multiple sclerosis, and cerebral palsy combined (Hirtz et al., 2007). It is estimated that 2.2 million people in the United States have epilepsy (Hirtz et al., 2007) and that 1 out of 26 people will develop epilepsy during their lifetime (Hesdorffer et al., 2011 ). Although most people with epilepsy are fully functioning members of society, adults with epilepsy have poorer social outcomes, including lower rates of marriage and higher rates of unemployment (Kobau et al., 2008). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Historically, epilepsy has been ignored by the public health community, despite the fact that there are more than 2 million people with epilepsy in the United States. Although epilepsy affects 1 in 26 people during their lifetime, the general public lacks basic knowledge and holds misperceptions about epilepsy that contribute to its associated stigma. Consequently, people with epilepsy continue to fare poorly, with lower physical, mental, and social well-being.Recently, the 2012 Institute of Medicine (IOM) report Epilepsy Across the Spectrum: Promoting Health and Understanding inspired a new sense of enthusiasm in the epilepsy community that can serve as a catalyst to change public perceptions about epilepsy. To erase stigma, the IOM committee made recommendations in two areas: (a) informing the media and (b) coordinating public awareness. The committee also identified eight key messages about epilepsy that the public should know. Health promotion and education professionals can play a critical role in disseminating these messages to the general public in their local communities and supporting interventions and policies to change the face of epilepsy.
    Full-text · Article · Mar 2014 · Health Promotion Practice
  • Source
    • "It is estimated that one in 26 people will develop epilepsy in their lifetime, amounting to almost 12 million people in the United States alone (Hesdorffer et al., 2011). Epilepsy is a group of conditions characterized by sporadic occurrence of seizures and unconsciousness . "
    [Show abstract] [Hide abstract]
    ABSTRACT: It is estimated that one in 26 people will develop epilepsy in their lifetime, amounting to almost 12 million people in the United States alone (Hesdorffer et al., 2011). Epilepsy is a group of conditions characterized by sporadic occurrence of seizures and unconsciousness. This severely limits the ability to perform everyday tasks and leads to increased difficulty with learning and memory, maintenance of steady employment, driving, and overall socioeconomic integration. A greater understanding of the cellular and molecular mechanisms underlying seizures and epilepsy is necessary, as it may lead to novel antiepileptic treatments. In this chapter, we will review the current literature surrounding the involvement of glial cells in epilepsy with particular emphasis on review of human tissue studies and some possible underlying mechanisms. Based on the current evidence and hypotheses of glial mechanisms in epilepsy, novel therapeutic opportunities for the treatment of epilepsy will also be presented.
    Full-text · Article · Jan 2013 · Neurochemistry International
Show more